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Design, synthesis, and in vitro and in vivo
characterization of 1-{4-[4-(substituted)piperazin-
1-yl]butyl}guanidines and their piperidine
analogues as histamine H3 receptor antagonists†‡
Marek Staszewski, *a Anna Stasiak,b Tadeusz Karcz,c Daniel McNaught Flores,d
Wiesława Agnieszka Fogel, b Katarzyna Kieć-Kononowicz, c
Rob Leursd and Krzysztof Walczyński *a
Previously, we have shown that 1-substituted-[4-(7-phenoxyheptylpiperazin-1-yl)butyl]guanidine with
electron withdrawing substituents at position 4 in the benzyl moiety exhibits high in vitro affinities toward
the guinea pig jejunal histamine H3 receptor with pA2 ranging from 8.49 to 8.43. Here, we present data on
the impact of replacement of the piperazine scaffold by the piperidine ring (compounds 2a and 2b), mov-
ing benzyl- and 4-trifluoromethylbenzyl substituents from position 1 to 3 of the guanidine moiety (com-
pounds 2c and 2d), which decreases the guanidine basicity (compound 2e), and the influence of individual
synthons (compounds 2f–h), present in the lead compounds 1b and 1c, on the antagonistic activity against
the histamine H3 receptor. Additionally, the most active compounds 1a, 1c, and 1d were evaluated for their
affinity to the rat histamine H3 receptor and the human histamine H3 and H4 receptors. It was also shown
that compounds 1a, 1c and 1d, given parenterally for five days, reduced the food intake of rats and did not
influence the brain histamine or noradrenaline concentrations; however, significantly reduced serotonin
and dopamine concentrations were found in rats administered with compounds 1a and 1c, respectively.
1. Introduction
Histamine is a biogenic amine implicated in a wide range of
physiological processes through the activation of four
G-protein coupled receptors (H1, H2, H3, and H4).
1 The post-
synaptic H1- and H2-receptors are mainly involved in the con-
trol of allergic response and gastric acid, respectively, while
the H4-receptor seems to be implicated in the inflammatory
process.2 Histamine H3 receptors are located on histaminer-
gic or non-histaminergic neurons, respectively acting as
autoreceptors or heteroreceptors, controlling the release and
synthesis of histamine3,4 and of multiple neurotransmitters
such as acetylcholine,5 norepinephrine6 and dopamine.7
These data suggested that histamine H3 receptor antagonists
could affect a number of behaviors and be useful in the treat-
ment of cognitive deficits associated with a variety of disease
states including Alzheimer's disease (AD),8 attention deficit
hyperactivity disorder (ADHD),9 schizophrenia,10 and
obesity.11
The first generation of active histamine H3 receptor li-
gands was based on a structurally modified imidazole ring.12
Unfortunately, further pharmacological investigations have
proved that the imidazole derivatives show poor brain pene-
tration, CYP450 inhibition, drug–drug interactions, liver toxic-
ity, etc.13,14 For these reasons, and after the successful cloning
of the human histamine H3 receptor by Lovenberg,
15 efforts
have been directed toward the discovery of histamine H3 re-
ceptor antagonists without an imidazole moiety as these com-
pounds may offer improvements in binding affinity, CNS pen-
etration and reduced potential for cytochrome P450 enzyme
inhibition.16,17
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Over the past fifteen years, the imidazole moiety has been
successfully replaced with pyrrolidine, piperidine, piperazine
and other basic tertiary amines.18,19
Although one of the first known histamine H3 receptor an-
tagonists was a guanidine derivative, impromidine, which
was found to be a potent agonist of the H2 receptor, only a
small number of compounds containing this structure ele-
ment are described. However, it appears that the guanidine
derivatives, both imidazole, i.e. 1-cyclohexylmethyl-3-[3-(1H-
imidazol-4-yl)propyl]guanidinine20 (Chart 1), and non-imidaz-
ole, i.e. compound JB 98064 (Chart 1),21 are potent and selec-
tive histamine H3 receptor antagonists.
Based on data reported in patent applications and chem-
istry papers, many efforts have been made to discover a
number of histamine H3 receptor ligands for treatment of
cognitive diseases/sleep disorders (e.g., Alzheimer, depres-
sion, anxiety, schizophrenia, and narcolepsy).22–24 Several of
these compounds have entered advanced clinical
phases.25,26 In addition to the search for histamine H3 re-
ceptor antagonists/inverse agonists for treatment of neuro-
degenerative diseases, efforts have been made to discover
histamine H3 receptor ligands for treatment of metabolic
diseases (e.g. obesity and dyslipidemia).27 Based on current
knowledge of the involvement of histamine in the regula-
tion of body weight, pharmacological manipulation of the
histaminergic system seems to be an obvious target for
anti-obesity drugs.28
Previously, we have reported the synthesis and preliminary
pharmacological in vitro characterization of a series of potent
histamine H3 receptor non-imidazole antagonists belonging
to the class of 1-substituted-1-{ω-[4-(ω-phenoxyalkyl)piperazin-
1-yl]alkyl}guanidines.29
The prominent members of this family are compounds
carrying electron-withdrawing substituents in position 1 of
the guanidine moiety or a chlorine atom at position 4 in the
benzene ring, 1a (ADS-1024; pA2 = 8.43), 1b (ADS-1020; pA2 =
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8.49), 1d, (ADS-1022; pA2 = 7.80), respectively, and an
unsubstituted benzyl residue 1c (ADS-1017; pA2 = 8.21) ((Chart 1)
for reference thioperamide (pA2 = 8.72)). These compounds were
also routinely screened for potency towards the histamine H1 re-
ceptor and were found to possess weak but competitive H1 an-
tagonistic activity (pA2 = 6.65, pA2 = 6.46, pA2 = 6.62, and pA2 =
6.70, respectively) for this site in the functional assay on isolated
tissue preparations of the guinea-pig ileum.
Throughout the study, we choose to retain the length of
the linkers connecting the phenoxy and guanidine residues
with the piperazine and piperidine rings (the alkyl chain con-
tains seven and four methylene groups, respectively), which
is optimal according to our previous results.29
In continuation of our search for new highly active and selec-
tive non-imidazole histamine H3 receptor antagonists, the first
part of this study aimed to clarify whether both nitrogen atoms
in the piperazine ring, present in the parent compounds 1a and
1b, are necessary to maintain a high activity or whether only one
of them (and which one) is absolutely necessary to retain the ac-
tivity. Therefore, two piperidine analogues, 2a (ADS-1025) and 2b
(ADS-1026) (Chart 1), of the lead compound 1b were synthesized
and pharmacologically evaluated (functionally on the in vitro test
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system using guinea pig jejunum preparations).30 Furthermore,
in the piperazine series, the influence of moving the benzyl- and
4-trifluoromethylbenzyl substituents from position 1 to 3 of the
guanidine moiety (compounds 2c (ADS-1029) and 2d (ADS-1028)
(Chart 1)), and introducing a nitrile group into the N2 guanidine
residue (compound 2e (ADS-1027) (Chart 1)) on the histamine
H3 receptor antagonistic activity was studied. Finally, three com-
pounds i.e. 1,4-bis{4-[1-(4-trifluoromethylbenzyl)guandin-1-
yl]but-1-yl}piperazine 2f (ADS-1030), 1,4-bisĲphenoxyheptyl)-
piperazine 2g (ADS-1031) and 1-benzyl-1-(7-phenoxyhept-1-
yl)guanidine 2h (ADS-1032) (Chart 1) were synthesized in order
to explain which part of the parent compound 1b plays the key
role in blocking the histamine H3 receptor.
Furthermore, all the newly synthesized compounds were
also tested for H1 antagonistic effects in vitro, following stan-
dard methods, using the guinea pig ileum.31
Additionally, the affinity of compounds 1a, 1c, and 1d –
the most active compounds that we have so far synthesized
in this series – was estimated to the recombinant rat hista-
mine H3 receptor (rH3R) transiently expressed in HEK-293T
cells and human histamine H3 and H4 receptors (hH3R,
hH4R) on cell membrane preparations from HEK293 with sta-
ble expression of the human histamine H3 receptor and from
CHO cells stably expressing the human histamine H4 recep-
tor (PerkinElmer, Waltham, MA), respectively. Furthermore,
these derivatives were subjected to in vivo evaluation of their
impact on feeding behavior and brain neurotransmitter sys-
tems after repeated peripheral administration to rats. Post-
mortem analyses of the rat brain tissues were also carried out
to determine the activities of MAO-A, MAO-B, and HNMT.
2. Results and discussion
2.1. Chemistry
The general synthetic procedures used in this study are illus-
trated in Schemes 1–7.
1-{4-[4-(7-Phenoxyheptyl)piperidin-1-yl]butyl}-1-[4-
(trifluoromethyl)benzyl]guanidine dihydrochloride 2a
(Scheme 1) was prepared by an eleven-step synthesis includ-
ing deprotonation of the 4-methyl group in 4-methylpyridine
3, followed by alkylation with 2-(6-bromohexyloxy)tetrahydro-
2H-pyran 4 to 7-(pyridin-4-yl)heptan-1-ol hydrochloride 2a.1,
hydrogenation with a catalytic amount of platinum dioxide in
anhydrous ethanol to 7-(piperidin-4-yl)heptan-1-ol 2a.2, reac-
tion with di-tert-butyl dicarbonate to 7-[1-(tert-
butoxycarbonyl)piperidin-4-yl]heptan-1-ol 2a.3, replacement of
the hydroxyl group by bromine with tetrabromomethane in
the presence of triphenylphosphine to 1-(tert-butoxycarbonyl)-
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4-(7-bromoheptyl)piperidine 2a.4, etherification with sodium
phenoxide 5 in anhydrous ethanol to 1-(tert-butoxycarbonyl)-
4-(7-phenoxyheptyl)piperidine 2a.5, removal of the N-Boc
protecting group in the presence of hydrochloric acid in diox-
ane to 4-(7-phenoxyheptyl)piperidine 2a.6, N-alkylation with
4-bromobutyronitrile 6 in the presence of potassium carbon-
ate in acetonitrile to 4-[4-(7-phenoxyheptyl)piperidin-1-
yl]butanenitrile 2a.7, reduction with LiAlH4 in dry ethyl ether
to 4-[4-(7-phenoxyheptyl)piperidin-1-yl]butan-1-amine 2a.8,
N-acylation with 4-(trifluoromethyl)benzoyl chloride 7 in the
presence of triethylamine to N-{4-[4-(7-phenoxyheptyl)-
piperidin-1-yl]butyl}-4-(trifluoromethyl) benzamide 2a.9, reduc-
tion with LiAlH4 in dry ethyl ether to 4-[4-(7-
phenoxyheptyl)piperidin-1-yl]-N-[4-(trifluoromethyl)benzyl]-
butan-1-amine 2a.10, guanylation with 1,3-bisĲtert-
butoxycarbonyl)-2-methyl-2-thiopseudourea in the presence of
triethylamine and 10% excess of mercuryĲII) chloride to 2,3-
diĲtert-butoxycarbonyl)-1-{4-[4-(7-phenoxyheptyl)piperidin-1-yl]-
butyl}-1-[4-(trifluoromethyl)benzyl]guanidine 2a.11, and finally
acid deprotection of the product from the guanylation to




(Scheme 2) was prepared by eight-step synthesis including
conversion of 4-piperidine butyric acid hydrochloride 8 to
methyl 4-(piperidin-4-yl)butanoate 2b.1, formation of
4-(piperidin-4-yl)butanamide 2b.2 by the reaction of the ester
2b.1 with aqueous ammonium hydroxide, N-alkylation of 2b.2
with 7-phenoxyheptyl bromide to 4-[1-(7-phenoxyheptyl)-
piperidin-4-yl]butanamide 2b.3, reduction with LiAlH4 in dry
ethyl ether to 4-[1-(7-phenoxyheptyl)piperidin-4-yl]butan-1-
amine 2b.4, N-acetylation with 4-(trifluoromethyl)benzoyl chlo-
ride 7 in the presence of triethylamine to N-{4-[1-(7-
phenoxyheptyl)piperidin-4-yl]butyl}-4-(trifluoromethyl)-
benzamide 2b.5, reduction with LiAlH4 in dry ethyl ether to
4-[1-(7-phenoxyheptyl)piperidin-4-yl]-N-[4-(trifluoromethyl)-
benzyl]butan-1-amine 2b.6, guanylation with 1,3-bisĲtert-
butoxycarbonyl)-2-methyl-2-thiopseudourea in the presence of
triethylamine and 10% excess of mercuryĲII) chloride to 2,3-
diĲtert-butoxycarbonyl)-1-[4-[1-(7-phenoxyheptyl)piperidin-4-yl]-
butyl]-1-[4-(trifluoromethyl)benzyl]-guanidine 2b.7, and finally
acid deprotection of the product from the guanylation to
1-{4 - [1 - (7 -phenoxyhepty l )piperidin-4 -y l ]buty l} -1 - [4 -
(trifluoromethyl)benzyl]-guanidine dihydrochloride 2b.
1-Benzyl-3-{4-[4-(7-phenoxyheptyl)piperazin-1-yl]butyl}-
guanidine trihydrochloride 2c and 1-[4-[4-(7-phenoxyheptyl)-
piperazin-1-yl]butyl]-3-[4-(trifluoromethyl)benzyl]guanidine tri-
hydrochloride 2d were prepared as outlined in Scheme 3.
Treatment of the appropriate benzyl bromide 10 and 11 with
1,3-bisĲtert-butoxycarbonyl)-2-methyl-2-thiopseudourea in the
presence of 60% sodium hydride oil dispersion in DMF
afforded 1,3-diĲtert-butoxycarbonyl)-1-benzyl-2-methyl-2-thio-
pseudourea 2c.1 and 1,3-diĲtert-butoxycarbonyl)-1-[4-
(trifluoromethyl)benzyl]-2-methyl-2-thiopseudourea 2d.1, re-
spectively. Compounds 2c.1 and 2d.1 were reacted with 4-[4-
(7-phenoxyheptyl)piperazin-1-yl]butan-1-amine 12 in a mixture




2d.2, respectively. Finally, compounds 2c.2 and 2d.2 were
treated with HCl in dioxane to cleave the Boc moieties respec-
tively, affording compounds 2c and 2d in quantitative yields.
The synthesis of 1-benzyl-3-cyano-1-{4-[4-(7-phenoxyheptyl)-
piperazin-1-yl]but-1-yl}guanidine trihydrochloride 2e was
Scheme 3 Synthesis of 1-benzyl-3-{4-[4-(7-phenoxyheptyl)piperazin-1-yl]butyl}guanidine trihydrochloride 2c (ADS-1029) and 1-[4-[4-(7-
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Scheme 4 Synthesis of 1-benzyl-3-cyano-1-{4-[4-(7-phenoxyheptyl)piperazin-1-yl]but-1-yl}guanidine trihydrochloride 2e (ADS-1027).
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carried out as outlined in Scheme 4. Treatment of N-cyano-
diphenylimidocarbonate 13 with a 10% ammonia solution in
methanol afforded 1-cyano-2-phenylisourea 2e.1. The reaction
of N-benzyl-4-[4-(7-phenoxyheptyl)piperazin-1-yl]butan-1-amine
14 with guanylating reagent 2e.1 in acetonitrile yielded 2e.2
which was converted into trihydrochloride salt 2e in 16% hy-
drogen chloride–methanol solution.
1,4-Bis{4-[1-(4-trifluoromethylbenzyl)guandin-1-yl]but-1-yl}-
piperazine tetrahydrochloride 2f (Scheme 5) was prepared by
six-step synthesis including bis-N-alkylation of piperazine 15
with 4-bromobutyronitrile 6 in the presence of potassium
carbonate in acetonitrile to 1,4-bisĲ4-nitrilobutyl)piperazine
2f.1, reduction with LiAlH4 in dry ethyl ether to 1,4-bisĲ4-
aminobutyl)piperazine 2f.2, bis-N-acylation with
4-(trifluoromethyl)benzoyl chloride 7 in the presence of tri-
ethylamine to 1,4-bisĳN-(4-trifluoromethylbenzoil)aminobut-4-
yl]piperazine 2f.3, reduction with LiAlH4 in dry ethyl ether
to 1,4-bisĳN-(4-trifluoromethylbenzyl)aminobut-4-yl]piperazine
2f.4, guanylation with 1,3-bisĲtert-butoxycarbonyl)-2-methyl-2-
thiopseudourea in the presence of triethylamine and 10%
excess of mercuryĲII) chloride to 1,4-bis{4-[1-(4-
trifluoromethylbenzyl)-2,3-diĲtert-butyloxycarbonyl)guandin-1-
yl]but-1-yl}piperazine 2f.5, and finally acid deprotection of




(Scheme 6) was obtained by condensing 2 moles of
7-phenoxyheptylbromide 9 with piperazine 15 in acetonitrile
with the presence of K2CO3. The free base was treated with a
4 M solution of hydrogen chloride–dioxane and dihydro-
chloride was precipitated with dry methanol.
1-Benzyl-1-(7-phenoxyhept-1-yl)guanidine fumarate 2h
(Scheme 7) was prepared by six-step synthesis including
etherification of sodium phenoxide 5 with 7-bromo-
heptanenitrile 16 to 7-phenoxyheptanenitrile 2h.1, reduction
Scheme 6 Synthesis of 1,4-bisĲ7-phenoxyheptyl)piperazine dihydrochloride 2g (ADS-1031).
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with LiAlH4 in dry ethyl ether to 7-phenoxyheptan-1-amine
2h.2, N-acylation with benzoyl chloride 17 in the presence of
triethylamine to N-(7-phenoxyheptyl)benzamide 2h.3, reduc-
tion with LiAlH4 in dry ethyl ether to N-benzyl-7-
phenoxyheptan-1-amine 2h.4, guanylation with 1,3-bisĲtert-
butoxycarbonyl)-2-methyl-2-thiopseudourea in the presence of
triethylamine and 10% excess of mercuryĲII) chloride to
1-benzyl-1-(7-phenoxyhept-1-yl)-2,3-diĲtert-butyloxycarbonyl)-
guanidine 2h.5, and finally acid deprotection of the product
from the guanylation to 1-benzyl-1-(7-phenoxyhept-1-
yl)guanidine fumarate 2h.
Detailed synthetic procedure and analytical data for com-
pounds 2a.1–2a.11; 2b.1–2b.7; 2c.1, 2c.2; 2d.1, 2d.2; 2e.1,
2e.2; 2f.1–2f.5, and 2h.1–2h.5 are shown in Appendix A (sub-
section 1): ESI.‡
2.2. Pharmacology
2.2.1. In vitro pharmacological studies
2.2.1.1. Histamine H3 receptor antagonistic activity of
compounds 1a–d and 2a–h. The compounds were tested
in vitro as histamine H3 receptor antagonists against
histamine H3 receptor agonist-induced inhibition of the elec-
trically evoked contraction of the guinea-pig jejunum.30 The
potencies of the newly synthesized compounds 2a–e and 2f–h
are reported in Table 1 including the previously described
data for compounds 1a–d (ref. 29) (Table 1). Derivatives 2a–h
show weak to pronounced antagonist activity against the his-
tamine H3 receptor.
Recently, we described a novel 1-{4-[4-(7-phenoxyheptyl)-
piperazin-1-yl]butyl}-1-[4-(substituted)benzyl]guanidine series29
Table 1 Histamine H3- and H1-receptor antagonistic potency in the in vitro test system in the Guinea pig jejunum and radioligand binding results on
human histamine H3 and H4 receptors for compounds 1a–d and 2a–h
Cpd.








1a (ref. 29) 8.43 (0.11) 10 (3) 6.65 (0.08) 9 (3) 7.8 ± 0.1 6.84 ± 0.02 5.92 ± 0.01 8.3
1b (ref. 29) 8.49 (0.05) 13 (4) 6.46 (0.06) 9 (3)
1c (ref. 29) 8.21 (0.05) 12 (4) 6.70 (0.10) 12 (4) 7.9 ± 0.1 6.80 ± 0.04 5.49 ± 0.07 20.9
1d (ref. 29) 7.80 (0.1) 9 (3) 6.62 (0.15) 15 (5) 7.6 ± 0.1 6.56 ± 0.03 5.97 ± 0.03 3.9
2a 7.90 (0.05) 12 (4) 7.19 (0.05) 8 (2)
2b 8.35 (0.08) 12 (4) 6.90 (0.06) 12 (4)
2c 8.10 (0.06) 12 (4) 7.10 (0.11) 8 (2)
2d 7.97 (0.02) 9 (3) 7.18 (0.01) 8 (2)
2e 7.30 (0.08) 12 (4) 6.97 (0.16) 12 (3)
2f 7.99 (0.08) 12 (4) 7.22 (0.10) 12 (3)
2g 5.78 (0.13) 9 (3) NA
2h 5.78 (0.03) 9 (3) 6.80 (0.25) 8 (2)
Thioperamide 8.98 (0.08) 16 (5) 7.9 ± 0.1 6.75 ± 0.11 7.34 ± 2.55 0.3
Pyrilamine 9.18 (0.05) 20 (5)
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with various substituents at position 4 in the benzyl moiety.
The introduction of strong electron-withdrawing substituents
led to compounds 1a (pA2 = 8.43) and 1b (pA2 = 8.49) show-
ing the highest potency for that series. Slightly lower potency
was shown by derivative 1c (pA2 = 8.21) bearing an
unsubstituted benzyl moiety. Additionally, all the compounds
(1a–1d) showed weak, but competitive H1-antagonistic activ-
ity, with pA2 ranging from 6.46 to 6.70.
With the aim of optimizing the structure of the lead com-
pound 1b, we wanted to clarify whether both nitrogen atoms
in the piperazine ring, present in the parent compound 1b,
are necessary to maintain a high activity or whether only one
of them (and which one) is absolutely necessary to retain the
activity. Therefore, two piperidine analogues, 2a – where the
butyl-[4-(trifluoromethyl)benzyl]guanidine residue was directly
bonded to the piperidine nitrogen, and 2b – where the
7-phenoxyheptyl moiety was attached to the piperidine nitro-
gen, were synthesized and pharmacologically evaluated. On
comparing the potency of 2a (pA2 = 7.90) and 2b (pA2 = 8.35)
with that of the parent compound 1b (pA2 = 8.49; Table 1), it
was shown that the piperidine analogues possessed slightly
lower antagonistic activity than the lead compound 1b
containing the piperazine scaffold, but derivative 2b pos-
sessed higher potency to the H1 receptor (pA2 = 6.90) than
the parent compound 1b (pA2 = 6.46). Taking into consider-
ation the obtained results, we chose to retain the 1-butyl-4-(7-
phenoxyheptyl)piperazine moiety as an optimal fragment for
further structural modification. Therefore, the influence of
moving the benzyl- and 4-trifluoromethylbenzyl substituents
from N1 to the N3 position of the guanidine moiety in com-
pounds 2c and 2d (Table 1) on the antagonistic activity
against the histamine H3 receptor was investigated. As seen
in the case of the piperidine analogues, both 1,3-disubstituted
guanidines (2c and 2d) were less active (pA2 = 8.10 and pA2 =
7.97) than the corresponding 1,1-disubstituted guanidines 1c
and 1b (pA2 = 8.21 and pA2 = 8.49, respectively). Slightly
higher potency was demonstrated by derivative 2c with an
unsubstituted benzyl ring than its 4-trifluoromethylbenzyl an-
alogue 2d. Additionally, in order to decrease the guanidine
basicity, a nitrile group was introduced into the N2 nitrogen
of derivative 1c which resulted in compound 2e showing the
lowest potency (pA2 = 7.3) within the series of compounds
2a–e (Table 1). Because of the lower potency of 2e compared
to 1c, we might conclude that the decreasing basicity of the
N2 nitrogen has a negative effect on blocking the histamine
H3 receptor.
Finally, in order to explain which synthon of the parent
compounds 1b and 1c plays the key role in blocking the
Fig. 1 Daily food consumption during pre-test (three days) and five days of treatment with the newly synthesized histamine H3 receptor antago-
nists 1a, 1c, and 1d, and ciproxifan. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, was used as a reference compound. The me-
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histamine H3 receptor, three compounds were synthesized
and pharmacologically evaluated in vitro (Table 1): 1,4-bis{4-
[1-(4-trifluoromethylbenzyl)guandin-1-yl]but-1-yl}piperazine
tetrahydrochloride 2f, 1,4-bisĲ7-phenoxyheptyl)piperazine 2g,
and 1-benzyl-1-(7-phenoxyhept-1-yl)guanidine 2h. Bisguanidine
derivative 2f showed potency (pA2 = 7.99; Table 1) on the
same level as compound 2d (pA2 = 7.97; Table 1). In the case
of bisĲ7-phenoxyheptyl) derivative 2g, a drastic reduction of
affinity (pA2 = 5.78; Table 1) was observed. Removal of the
1-butylpiperazine fragment from derivative 1c resulted in
compound 2h, with only a weak activity (pA2 = 5.78; Table 1)
against the H3 receptor. Based on the obtained results, it is
seen that the trifluoromethylbenzylguandinbutyl moiety plays
the key role in blocking the histamine H3 receptor in the pi-
perazine series.
All the graphs of antagonism by 2a–h and thioperamide
and the inhibitory effect of R-(−)-α-methyl-histamine (RAMH)
on the electrically induced contraction of guinea-pig ileum
strips are shown in Appendix B (subsection 2.2.1; Fig. 1):
ESI.‡
2.2.1.2. H1 antagonistic activity of compounds 2a–h. Due to
the fact that the most active previously obtained compounds
(1a–d) showed weak, competitive H1-antagonistic activity, all
the newly synthesized compounds (2a–h) were also tested for
H1 antagonistic effects in vitro, following standard methods,
using the guinea pig ileum.31 The highest potency to the H1
receptor was seen for compounds 2a, 2c, 2d and 2f (pA2 =
7.19, pA2 = 7.10, pA2 = 7.18, and pA2 = 7.22, respectively;
Table 1). A similar potency for the histamine H1 receptors
and histamine H3 receptors was observed for compound 2e
(H1pA2 = 6.97, H3pA2 = 7.30) (Table 1). In the case of
compound 2h (where the butylpiperazine fragment was
removed) the antagonistic activity against the H1 receptor
was higher (pA2 = 6.8) than that against the histamine H3
receptor (pA2 = 5.78; Table 1). No activity for the H1 receptor
was observed for derivative 2g only, but a drastic reduction of
potency was observed for the histamine H3 receptor (pA2 =
5.78), compared to the parent compound 1c (pA2 = 8.21). All
the graphs of antagonism by 2a–h and pyrilamine and the
inhibitory effect of histamine on the contraction of guinea-
pig ileum strips are shown in Appendix B (subsection 2.2.2;
Fig. S2): ESI.‡
2.2.2. Histamine H3 and H4 receptor affinity. Taking into
consideration the potency of the newly synthesized com-
pounds 2a–h, the parent compounds 1a, 1c, and 1d demon-
strated significantly higher potency. For this reason, deriva-
tives 1a, 1c, and 1d were evaluated for their affinity to the
recombinant rat histamine H3 receptor (rH3R) and human
histamine H3 and H4 receptors (hH3R and hH4R).
2.2.2.1. Histamine H3 receptor affinity studies. The affinity
of the aforementioned compounds was evaluated by
measuring the displacement curve of [3H]-Nα-
methylhistamine on the rat (rH3R) histamine H3 receptor in
HEK-293T cell membranes as described by Bongers.32
2.2.2.1.1. Competitive binding of rat histamine H3 receptor
ligands. Saturation of the rat histamine H3 receptor –
membranes expressing rH3R were incubated with different
concentrations of [3H]-Nα-MH (0–20 nM) in the absence or
presence of unlabeled thioperamide (10 μM) to determine
the total and non-specific binding, respectively, for 2 h at 25
°C. The reaction was terminated by rapid filtration on GF/C
96 well plates and the bound radioligand was measured by
scintillometry. Specific binding was defined as the difference
between the total and non-specific binding conditions. A rep-
resentative graph of the saturation of the rat histamine H3 re-
ceptor can be found in Appendix B (subsection 2.2.3; Fig. S3):
ESI.‡
Analysis of the [3H]-Nα-MH saturation binding yielded on
the rat histamine H3 receptor a KD value of 2.72 ± 0.34 nM
and a Bmax value of 2715 ± 445 fmol mg
−1 protein and on the
human histamine H3 receptor a KD value of 0.9 ± 0.08 nM
and a Bmax value of 632 ± 52 fmol mg
−1 protein.
Competitive radioligand binding – the affinity of 1a, 1c,
1d, histamine, and thioperamide – the reference compound,
was determined by measuring the displacement curves of
[3H]-Nα-methylhistamine binding on the rat histamine H3 re-
ceptor expressed in HEK-293T membranes. Derivatives 1c
and 1a possess a high nanomolar affinity for the rat hista-
mine H3 receptor with a pKi value of 7.9 ± 0.1 and 7.8 ± 0.1,
respectively. Slightly lower affinity is seen for compound 1d
with a pKi value of 7.6 ± 0.1 in comparison with the pKi of
thioperamide (pKi value = 7.9 ± 0.1). All the investigated com-
pounds show slightly higher affinity than histamine (pKi =
7.3 ± 0.1). A representative graph of the competitive binding
of histamine H3 receptor ligands on the rat histamine H3 re-
ceptor can be found in Appendix B (subsection 2.2.2.1; Fig.
S4): ESI.‡
2.2.2.2. Competitive binding of human H3 and H4 receptor
ligands. Previously, compounds 1a, 1c, and 1d, and
thioperamide – the reference compound – were investigated
for human histamine H3 and H4 receptor in vitro binding
studies.33 [3H]Nα-methylhistamine was used as the
radioligand in binding assays to test the affinity to the human
recombinant histamine H3 receptor stably expressed in
HEK293 cells34 (the experimentally determined radioligand
KD value of 0.34 nM was used). [
3H]histamine was used as the
radioligand in binding assays to test the affinity on
membrane preparations from CHO cells, expressing the
recombinant human histamine H4 receptor
35 (the
experimentally determined radioligand KD value of 9.70 nM
was used). Pharmacological results are presented in Table 1.
Based on preliminary functional pharmacological studies,
subsection 2.2.1.1, the radioligand binding studies confirmed
the affinity of the investigated derivatives 1a, 1c, and 1d with
the human histamine H3 receptor (Table 1). All the investi-
gated compounds showed good affinities for the human his-
tamine H3 receptor in a pKi range of 6.84–6.56 in comparison
with the pKi of thioperamide (Ki value 6.75). The competitive
radioligand binding assay on hH4R revealed weak selectivity
towards the human histamine H3 receptor for derivatives 1a
and 1d carrying a substituent at position 4 in the N-benzyl-
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histamine H3 receptor was shown for unsubstituted N-benzyl-
guanidine derivative 1c (Table 1). This compound also showed
higher affinity to the human histamine H3 receptor with a pKi
value of 6.80 compared with thioperamide (pKi value = 6.75).
2.2.3. Verification of in vivo activity for compounds 1a, 1c
and 1d. Furthermore, derivatives 1a, 1c, and 1d were
subjected to preliminary in vivo evaluation of their impact on
brain neurotransmitter systems. This assessment concerned:
- The effects of the compounds on the feeding behavior of
rats after their repeated peripheral administration.
- The influence on the cerebral amine neurotransmitter
concentrations, as well as the activity of monoamine oxidases
A and B and histamine N-methyltransferase. The latter was
accomplished by postmortem analyses of the brain tissue of
the treated rats.
Derivatives 1a, 1c and 1d were chosen for the aforemen-
tioned studies and not one of the latest compounds, as for
this class of non-imidazole antagonists so far no proof of in
vivo activity has been reported. As such, we have chosen the
best compounds available for the in vivo studies.
In accordance with the earlier reported experimental
data,36–38 it was assumed that if a histamine H3 receptor an-
tagonist subcutaneously injected into rats crossed the blood–
brain barrier (BBB), it would affect the animal food consump-
tion. To evaluate the central effects of peripheral administra-
tion of 1a, 1c, and 1d to rats, the feeding behavior of rats was
monitored after each drug administration.
As presented in Fig. 2, treatment of rats with either of the
four histamine H3 receptor antagonists 1a (3 mg kg
−1 s.c.), 1c
(3 mg kg−1 s.c.) and 1d (3 mg kg−1 s.c.) and ciproxifan (3 mg
kg−1 s.c. – based on the literature data39 the dose 3 mg kg−1
was selected to evaluate the central effects of peripheral ad-
ministration of derivatives 1a, 1c, and 1d to rats on their
feeding behavior) over a period of five days evoked a statisti-
cally significant reduction in the amount of consumed food
by rats compared to the pre-treatment period.
Based on in vitro and in vivo studies in the literature,40
ciproxifan was shown as a pure competitive antagonist of the
histamine H3 receptor. Therefore, ciproxifan was used for the
in vivo studies, instead of thioperamide because the in vivo
potency of thioperamide is rather low compared with it's
in vitro potency, which can result in restricted drug bioavail-
ability, particularly its brain penetration.
Male Wistar or Lewis rats were used to verify the in vivo ef-
ficacy of the selected histamine H3 receptor ligands. Four
days before the experiment, the rats were placed individually
in metabolic cages (Tecniplast Gazzada, Italy) with free access
to feed and water. After a one-day adaptation period to the
new conditions, food consumptions were monitored daily,
between 8:00–8:30 a.m., for the next three days and the
means related to the pretreatment were calculated. Each of
the tested compounds was given in a dose of 3 mg kg−1 per
day, subcutaneously, for five days. Ciproxifan was employed
as the reference. Every morning, the consumed food was
recorded. Fig. 1 illustrates a decrease in the daily food intake
upon the repeated drug administration.
In Fig. 2 the effect of five-day treatment versus
pretreatment is presented as related to the consumed food. It
can be inferred from these data that all the tested histamine
H3 receptor ligands have entered the brain for they signifi-
cantly modified the feeding pattern, with compound 1d
exhibiting a potency similar to that of ciproxifan.
A statistically significant decline in food consumption was
noted in rats treated with all the compounds examined
(Fig. 1 and 2); 1d, being the most effective, caused a total of
13.5% reduction in food consumption compared with the re-
sults recorded before administration of the drug (7.54 ± 0.17
vs. 6.52 ± 0.13 g per 100 g of body weight) (Fig. 2, p < 0.001).
This effect was most noticeable on the 5th day (Fig. 1) and
was similar to that caused by ciproxifan (Fig. 1 and 2). 1a de-
creased the pellet consumption to a lesser extent by 10%, i.e.
7.42 ± 0.22 vs. 6.73 ± 0.17 g per 100 g of body weight, P =
0.0205 (Fig. 2). The lowest reduction in food consumption
was noted for compound 1c.
2.2.3.1. Post-mortem biochemical analysis of the brain
tissues of 1a, 1c, and 1d treated rats. To find out whether
there are any post-treatment alterations in the cerebral amine
neurotransmitter systems, after the last record was taken in
metabolic cages the rats were sacrificed and their brains were
collected to measure the amine concentrations by RIA or
ELISA (DIAsource ImmunoAssays S.A., Nivelles, Belgium), as
well as the histamine N-methyltransferase and monoamine
oxidase (MAO) activities by radioisotopic assays.
None of the tested compounds influenced the histamine
or noradrenaline concentrations in the rat cortex. However,
cortical concentrations of serotonin and dopamine were sig-
nificantly lower in rats administered with compounds 1a and
1c, respectively, when compared to the concentrations mea-
sured in ciproxifan-treated rats. The serotonin concentration
Fig. 2 The effect of the newly synthesized histamine H3 receptor
antagonists 1a (s.c. 3 mg kg−1 daily for 5 days), 1c (s.c. 3 mg kg−1 daily
for 5 days), and 1d (s.c. 3 mg kg daily for 5 days) on food consumption.
Ciproxifan (s.c. 3 mg kg−1 daily for 5 days), a histamine H3-receptor
antagonist/inverse agonist, was used as a reference compound. The
values are mean ± sem. All white bars correspond respectively to food
consumed during the 3-day pre-test, whereas bars with patterns cor-
respond to food consumed during the 5-day treatment with appropri-
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was roughly one third and the dopamine concentration two-
thirds of those obtained in ciproxifan-treated rats. A repre-
sentative graph of cerebral amine neurotransmitter concen-
tration in rats subchronically treated with the newly synthe-
sized 1a, 1c, and 1d histamine H3 receptor antagonists and
the reference compound ciproxifan can be found in Appendix
B (subsection 2.2.3.1; Fig. S5): ESI.‡
The activities of the brain catabolic enzymes have not
been affected by the tested histamine H3 receptor ligands.
Clearly, the MAO enzymes do not contribute to the changes
in serotonin or dopamine concentrations resulting from the
treatment with 1a, 1c, and 1d. The effect of subchronic ad-
ministration of 1a, 1c and 1d (s.c. 3 mg kg−1 daily for 5 days)
and ciproxifan (s.c. 3 mg kg−1 daily for 5 days) on cerebral
MAO and HNMT activities can be found in Appendix B (sub-
section 2.2.3.1; Table S1): ESI.‡
Conclusions
Of both series (1a–d and 2a–h), the 1-substituted-1-{4-[4-(7-
phenoxyalkyl)piperazin-1-yl]butyl}guanidine derivatives 1a (pA2
= 8.43) and 1b (pA2 = 8.49) carrying electron-withdrawing sub-
stituents at position 4 in the benzene ring demonstrated the
highest in vitro potency as histamine H3 receptor antagonists.
For 1a and 1b, the in vitro potency was found to slightly de-
crease when the piperazine scaffold was replaced by a piperi-
dine ring (2a – pA2 = 7.90 and 2b – pA2 = 8.35). In the pipera-
zine series, transfer of the benzyl- and 4-trifluoromethylbenzyl
substituents from the N1 to the N3 position of the guanidine
moiety resulted in further decreases in potency (2c – pA2 =
8.10 and 2d – pA2 = 7.97). Decreasing the guanidine basicity
following the introduction of a nitrile substituent into the N2
nitrogen derivative 1c resulted in compound 2e, showing the
lowest potency (pA2 = 7.3) within the series of compounds
2a–e. In the series of compounds 2f–h, where the synthons:
phenoxyheptyl-, trifluoromethylbenzylguandinbutyl-, and
1-piperazinynylobutyl- were removed from the structure of the
parent compound 1b, only bisguanidine derivative 2f showed
a similar potency (pA2 = 7.99) to 2d (pA2 = 7.97). Compounds
2g and 2h showed weak potency (pA2 = 5.78, pA2 = 5.78, re-
spectively) for the histamine H3 receptor. All the newly
obtained compounds 2a–h (pA2 from 6.90 to 7.22) exhibited
higher potency for the H1 receptor than the lead compounds
1a–d (pA2 from 5.85 to 6.7). Competitive radioligand binding
studies on the rat histamine H3 receptors for compounds 1a,
1c and 1d showed an affinity (pKi from 7.9 to 7.6, respec-
tively) on a comparable level to the reference compound –
thioperamide (pKi = 7.9), confirming the high potency shown
by the tested compounds in the functional assay in the
guinea pig jejunum. Additionally, competitive radioligand
binding studies on the human histamine H3 receptor also
showed good affinity for these compounds with a pKi value
ranging from 6.84 to 6.56 while a pKi value of 6.75 was found
for thioperamide. The competitive radioligand binding assay
on the H4 receptor revealed weak selectivity towards the hu-
man histamine H3 receptor for compounds 1a and 1d. The
highest histamine H3 receptor selectivity was seen for com-
pound 1c; ratio KiH4/KiH3 = 20.9.
Compounds 1a, 1c and 1d, given parenterally for five days,
reduced the food intake of rats. Of the tested compounds,
the best turned out to be 1d which had a similar potency to
ciproxifan in terms of the food consumption decrease; a
somewhat lower effect was found for 1c and a lower one for
1a. Post-mortem biochemical analysis of the brain tissues of
1a, 1c, and 1d treated rats indicates that none of the tested
compounds influenced the brain histamine or noradrenaline
concentrations. However, significantly reduced serotonin and
dopamine concentrations were found in the rats adminis-
tered with compounds 1a and 1c, respectively.
The high potency and affinity for H3 receptors and the




All melting points (mp) were measured in open capillaries on
electrothermal apparatus and are uncorrected. All 1H NMR
and 13H NMR spectra were recorded on Varian Mercury VX
300 MHz and Bruker Avance III 600 MHz (1H NMR spectra
were run at 600 MHz, while 13C NMR spectra were run at
150.95 MHz) spectrometers in deuterated dimethyl sulfoxide
(DMSO-d6), chloroform-d and deuterium oxide. Chemical
shifts are expressed in ppm downfield from internal TMS as
a reference. 1H NMR data are reported in the order: multi-
plicity (br, broad; s, singlet; d, doublet; t, triplet; q, quartet;
qt, quintet; m, multiplet; *, exchangeable by deuterium ox-
ide), number of protons, and approximate coupling constant
in Hertz. Elemental analysis (C, H, and N) for all compounds
was conducted on a Perkin Elmer Series II CHNS/O Analyzer
2400 and results are within ±0.4% of the theoretical values.
Reactions were monitored by thin-layer chromatography
(TLC) on silica gel 60 F254 plates (Merck) and visualized
using a UV Lamp (254 nm) and cerium molybdate stain.
Flash column chromatography was performed on silica gel
60 Å 50 mm (J. T. Baker B. V.) and Normasil 60 silica gel 40–
63 μm (VWR Chemicals), employing the eluent indicated by
TLC.
2-(6-Bromohexyloxy)tetrahydro-2H-pyran, di-tert-butyl
dicarbonate, tetrabromomethane, 4-bromobutyronitrile, 4 M
solution hydrogen chloride in dioxane, 4-(trifluoromethyl)-
benzoyl chloride, 4-piperidine butyric acid hydrochloride,
benzyl bromide, 4-(trifluoromethyl)benzyl bromide, and piper-
azine were purchased from commercial suppliers (Aldrich,
TCI, Fluorochem, Fluka) and used without further
purification.
N-Benzyl-4-(4-(7-phenoxyheptyl)piperazin-1-yl)butan-1-amine
was prepared according to Staszewski and Walczyński.29
3.1. Chemistry
General procedure for the preparation of guanidines 2a,
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bisĲtert-butoxycarbonyl)guanidine (2a.11, 2b.7, 2c.2, 2d.2, 2f.5
and 2h.5) (1 eq.) in chloroform, a 4 M solution of hydrogen
chloride–dioxane (20 eq.) was added dropwise. The reaction
was stirred overnight at room temperature and then the sol-
vent was removed under vacuum. The crude product was
evaporated twice with chloroform and twice with EtOAc, then
recrystallized from dry ethanol or methanol to yield the pure
product. In the case of compound 2h, the following proce-
dure was used: the crude product was evaporated twice from
chloroform and twice from EtOAc then evaporated, dissolved
in methanol, alkalized by 5% sol. of sodium hydroxide,
extracted with DCM and dried over Na2SO4. The crude prod-
uct was dissolved in methanol and 1 eq. fumaric acid was
added. After 30 minutes the solvent was evaporated, then the




C31H45F3N4O·2HCl. M = 619.65. White solid. 89.1% yield. mp:
159.6–161.5 °C. 1H NMR (600 MHz, D2O) δ ppm 7.82–7.81 (m,
2Harom., (CH)2CCF3), 7.52–7.51 (m, 2H
arom., (CHCH)2CCF3),
7.44–7.41 (m, 2Hphenoxy., C(CHCH)2CH), 7.10–7.07 (m, 3H
phenoxy.,
C(CHCH)2CH), 4.73 (s, 2H, CH2Ph), 4.15–4.13 (t, 2H, OCH2, J =
6.52 Hz), 3.52–3.47 (m, 4H: 2Halif. CH2CH2NC(N), 2H
piperidine
CHĲCH2CH2)2N), 3.06–3.04 (m, 2H, CH2N
piperidine), 2.88–2.84
(m, 2Hpiperidine, CHĲCH2CH2)2N), 1.99–1.97 (m, 2H
piperidine,
CHĲCH2CH2)2N), 1.83–1.78 (qt, 2H, OCH2CH2), 1.71–1.70 (m,
4H, NCH2CH2CH2CH2N), 1.57–1.55 (m, 1H
piperidine,
CHĲCH2CH2)2N), 1.51–1.46 (m, 2H, OCH2CH2CH2), 1.43–1.30
(m, 10Halif.: CHCH2, CH2CH2CH2).
13C NMR (600 MHz, DMSO)
δ ppm 158.54 (1Cquat./phenoxy., CO), 156.55 (1Cquat., CNH),
140.79 (1Cquat./arom., CCH2), 129.33 (2C
phenoxy., C(CHCH)2CH),
128.35, 128.14, 127.93, 127.72 (1Carom, CCF3), 127.36 (2C
arom.,
(CHCH)2CCF3), 126.81, 125.01, 123.20, 121.40 (1C, CF3), 125.43,
125.41 (2Carom., (CH)2CCF3), 120.27 (1C
phenoxy., C(CHCH)2CH),
114.29 (2Cphenoxy., C(CHCH)2CH), 67.15 (1C, PhOCH2), 55.32
(1C, CH2N
piperidine), 51.71 (1Cpiperidine, CHĲCH2CH2)2N), 51.70
(1Cpiperidine, CHĲCH2CH2)2N), 50.29 (1C, NCH2Ph), 47.86 (1C,
CH2CH2NC(N)), 35.19 (1C, OĲCH2)3CH2), 32.83 (1C
piperidine,
CHĲCH2CH2)2N), 28.94 (1C
piperidine, CHĲCH2CH2)2N), 28.67 (1C,
CH2CH2CH2), 28.57 (3C: 1C
piperidine, CHĲCH2CH2)2N, 2C
alif.,
CH2CH2CH2), 25.69 (1C, OĲCH2)2CH2), 25.38 (1C, CH2CH2CH2),
24.05 (1C, CH2CH2NC(N)), 20.02 (1C, CH2CH2CH2). Anal. calcd:
C, 60.09; H, 7.65; N, 9.04. Found: C, 59.69; H, 8.05; N, 9.06.
2b – 1-{4-[1-(7-phenoxyheptyl)piperidin-4-yl]butyl}-1-[4-
(trifluoro methyl)-benzyl]guanidine dihydrochloride.
C31H45F3N4O·2HCl·0.5H2O. M = 628.66. White solid. 96.6% yield.
mp: 88.2–90.2 °C. 1H NMR (600 MHz, D2O) δ ppm 7.81–7.79 (m,
2Harom., (CHCH)2CCF3), 7.53–7.52 (m, 2H
arom., (CHCH)2CCF3),
7.43–7.40 (m, 2Hphenoxy., C(CHCH)2CH), 7.09–7.05 (m, 3H
phenoxy.,
C(CHCH)2CH), 4.78 (s, 2H, CH2Ph), 4.12–4.09 (t, 2H, OCH2, J =
6.46 Hz), 3.52–3.50 (m, 2HPiperidine, CHĲCH2CH2)2N), 3.46–3.44
(m, 2H, CH2CH2NC(N)), 3.07–3.04 (m, 2H, CH2N
piperidine), 2.82–
2.78 (m, 2HPiperidine, CHĲCH2CH2)2N), 1.91–1.88 (m, 2H
Piperidine,
CHĲCH2CH2)2N), 1.83–1.79 (qt, 2H, OCH2CH2), 1.75–1.70 (m,
2H, CH2CH2N
piperidine), 1.66–1.61 (m, 2H, CH2CH2NC(N)), 1.52–
1.26 (m, 13H: 3HPiperidine, 10Halif., CHCH2, CH2CH2CH2).
13C
NMR (600 MHz, DMSO) δ ppm 158.36 (1Cquat./phenoxy., CO), 156.79
(1Cquat., CNH), 139.63 (1Cquat./arom., CCH2), 129.97 (2C
phenoxy.,
C(CHCH)2CH), 129.77, 129.55, 129.34, 129.11 (1C
arom, CCF3),
127.43 (2Carom., (CHCH)2CCF3), 126.98, 125.18, 123.38, 121.75
(1C, CF3), 125.92, 125.89 (2C
arom., (CH)2CCF3), 121.75 (1C
phenoxy.,
C(CHCH)2CH), 115.03 (2C
phenoxy., C(CHCH)2CH), 68.55 (1C,
PhOCH2), 57.07 (1C, CH2N
piperidine), 52.94 (2Cpiperidine,
CHĲCH2CH2)2N), 51.81 (1C, CH2Ph), 49.56 (1C, CH2CH2NC(N)),
34.43 (1C, CH2CH2CH2), 32.74 (1C, CH2CH2CH2), 29.20
(2Cpiperidine, CHĲCH2CH2)2N), 28.34 (1C
piperidine, CHĲCH2CH2)2N),
27.86 (1C, CH2CH2CH2), 26.61 (1C, CH2CH2CH2), 25.74 (1C,
CH2CH2CH2), 24.94 (1C, CH2CH2CH2), 23.27 (1C, CH2CH2CH2),
22.79 (1C, CH2CH2CH2). Anal. calcd: C, 59.23; H, 7.70; N, 8.91.
Found: C, 59.47; H, 7.87; N, 8.89.
2c – 1-benzyl-3-{4-[4-(7-phenoxyheptyl)piperazin-1-yl]butyl}-
guanidine trihydrochloride. C29H45N5O·3HCl·0.5H2O. M =
598.10. White solid. 95.3% yield. mp: 218.6–220.6 °C with
decomposition. 1H NMR (600 MHz, D2O) δ ppm 7.52–7.50 (m,
2Harom.), 7.46–7.42 (m, 5H: 2Hphenoxy., C(CHCH)2CH, 3H
arom.,
C(CHCH)2CH), 7.12–7.07 (m, 3H
phenoxy., C(CHCH)2CH), 4.52 (s,
2H, CH2Ph), 4.15–4.13 (t, 2H, OCH2, J = 6.48 Hz), 3.70 (br,
8Hpiperazine), 3.34–3.31 (m, 6H, CH2N
piperazine, CH2CH2NC(N)),
1.84–1.76 (m, 6H, CH2CH2CH2), 1.72–1.67 (qt, 2H, CH2CH2CH2),
1.53–1.46 (m, 6H, CH2CH2CH2).
13C NMR (600 MHz, DMSO) δ
ppm 158.54 (1Cquat./phenoxy., CO), 155.86 (1Cquat., CNH), 137.24
(1Cquat./arom., CCH2), 129.35 (2C
phenoxy., C(CHCH)2CH), 128.41
(2Carom., C(CHCH)2CH), 127.28 (1C
arom., C(CHCH)2CH), 127.06
(2Carom., C(CHCH)2CH), 120.25 (1C
phenoxy., C(CHCH)2CH), 114.32
(2Cphenoxy., C(CHCH)2CH), 67.14 (1C, PhOCH2), 55.52 (1C,
CH2N
piperazine), 55.12 (1C, CH2N
piperazine), 47.83 (4Cpiperazine),
43.89 (1C, NCH2Ph), 40.15 (1C, CH2CH2NC(N)), 28.47 (1C,
CH2CH2CH2), 28.09 (1C, CH2CH2CH2), 25.81 (1C, CH2CH2CH2),
25.53 (1C, CH2CH2CH2), 25.19 (1C, CH2CH2CH2), 22.79 (1C,
CH2CH2CH2), 20.15 (1C, CH2CH2CH2). Anal. calcd: C, 58.24; H,
8.26; N, 11.71. Found: C, 58.58; H, 8.61; N, 11.63.
2d – 1-{4-[4-(7-phenoxyheptyl)piperazin-1-yl]butyl}-3-[4-
(trifluoromethyl)-benzyl]guanidine trihydrochloride.
C30H44F3N5O·3HCl. M = 657.10. Light yellow solid. 90.9% yield.
mp: 227.4–229.4 °C with decomposition. 1H NMR (600 MHz,
D2O) δ ppm 7.79–7.78 (m, 2H
arom.), 7.57–7.55 (m, 2Harom.), 7.44–
7.41 (m, 2Hphenoxy., C(CHCH)2CH), 7.11–7.08 (m, 1H
phenoxy.,
C(CHCH)2CH), 7.06–7.05 (m, 2H
phenoxy., C(CHCH)2CH), 4.59 (s,
2H, CH2Ph), 4.11–4.09 (t, 2H, OCH2, J = 6.50 Hz), 3.72 (br,
8Hpiperazine), 3.36–3.31 (m, 6H: CH2N
piperazine, CH2CH2NC(N)),
1.85–1.76 (m, 6H, CH2CH2CH2), 1.73–1.68 (qt, 2H,
CH2CH2CH2), 1.50–1.44 (m, 6H, CH2CH2CH2).
13C NMR (600
MHz, DMSO) δ ppm 158.52 (1Cquat./phenoxy., CO), 155.94 (1Cquat.,
CNH), 142.28 (1Cquat./arom., CCH2), 129.31(2C
phenoxy.,
C(CHCH)2CH), 128.15, 127.94, 127.73, 127.52 (1C
arom., CCF3),
127.70 (2Carom., (CHCH)2CCF3), 126.83, 125.03, 123.23, 121.42
(1C, CF3), 125.22, 125.20 (2C




PhOCH2), 55.48 (1C, CH2N
piperazine), 55.06 (1C, CH2N
piperazine),
47.78 (4Cpip.), 43.36 (1C, NCH2Ph), 40.16 (1C, CH2CH2NC(N)),
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CH2CH2CH2), 25.52 (1C, CH2CH2CH2), 25.16 (1C, CH2CH2CH2),
22.72 (1C, CH2CH2CH2), 20.10 (1C, CH2CH2CH2). Anal. calcd: C,
54.84; H, 7.21; N, 10.66. Found: C, 54.91; H, 7.37; N, 10.61.
2f – 1,4-bis{4-[1-(4-trifluoromethylbenzyl)guandin-1-yl]but-1-
yl}piperazine tetrahydrochloride. C30H42F6N8·4HCl·1.5H2O. M =
801.58. White solid. 91.60% yield. mp: 261.2–263.4 °C with
decomposition. 1H NMR (600 MHz, D2O) δ ppm 7.82–7.81
(m, 4Harom.), 7.52–7.51 (m, 4Harom.), 4.80 (s, 4H, CH2Ph),
3.69–3.68 (m, 8Hpiperazine), 3.54–3.53 (m, 4H, CH2CH2N),
3.31–3.29 (m, 4H, CH2CH2N), 1.79–1.78 (m, 8H, CH2CH2CH2).
13C NMR (600 MHz, D2O) δ ppm 156.67 (2C
quat., CNH),
139.04 (2Cquat./arom., CCH2), 129.68, 129.47, 129.26, 129.05
(2Carom., CCF3), 126.93 (4C
arom., (CHCH)2CCF3), 126.75,
124.96, 123.16, 121.36 (2C, CF3), 125.86, 125.84 (4C
arom.,
(CH)2CCF3), 56.24 (2C, CH2CH2N), 56.23 (2C, CH2CH2N),
51.46 (2C, CH2PhCF3), 48.59, 48.56 (4C
piperazine), 23.51 (2C,
CH2CH2CH2), 20.63 (2C, CH2CH2CH2). Anal. calcd: C, 44.95;
H, 6.16; N, 13.98. Found: C, 45.28; H, 6.34; N, 13.65.
2h – 1-benzyl-1-(7-phenoxyhept-1-yl)guanidine fumarate.
C21H29N3O·C4H4O4. M = 455.54. White solid. 40.6% yield. mp:
103.4–105.0 °C. 1H NMR (600 MHz, CD3OD) δ ppm 7.40–7.38
(m, 2Harom., C(CHCH)2CH), 7.33–7.31 (m, 1H
arom.,
C(CHCH)2CH), 7.26–7.22 (m, 4H: 2H
phenoxy., C(CHCH)2CH),
2Harom., C(CHCH)2CH, 6.90–6.87 (m, 3H
phenoxy., C(CHCH)2CH),
6.69 (s, 2Hfum., CH), 4.62 (s, 2H, PhCH2), 3.96–3.94 (t, 2H, OCH2,
J = 6.37 Hz), 3.34–3.32 (t, 2H, CH2CH2C(N)N), 1.77–1.72 (qt, 2H,
CH2CH2CH2), 1.65–1.59 (qt, 2H, CH2CH2CH2), 1.49–1.44 (qt,
2H, CH2CH2CH2), 1.40–1.30 (m, 4H, CH2CH2CH2).
13C NMR
(600 MHz, CD3OD) δ ppm 171.17 (2C, CO), 160.55
(1Cquat./phenoxy., CO), 158.38 (1Cquat., CN), 136.42 (1Cquat./arom.),
136.12 (2C, CC), 130.39, 130.05 (4Carom., C(CHCH)2CH),




(2Cphenoxy., C(CHCH)2CH), 68.78 (1C, OCH2), 52.67 (1C, PhCH2),
49.87 (1C, CH2CH2C(N)N), 30.25 (1C, CH2CH2CH2), 30.04 (1C,
CH2CH2CH2), 28.07 (1C, CH2CH2CH2), 27.39 (1C, CH2CH2CH2),
26.99 (1C, CH2CH2CH2). Anal. calcd: C, 64.64; H, 7.38; N, 9.05.
Found: C, 64.86; H, 7.09; N, 9.12.
Synthesis of 1-benzyl-3-cyano-1-{4-[4-(7-phenoxyheptyl)-
piperazin-1-yl]but-1-yl}guanidine trihydrochloride 2e. To a so-
lution of 1-benzyl-3-cyano-1-[4-[4-(7-phenoxyheptyl)piperazin-1-
yl]butyl]guanidine (2e.2) (1 eq.) in methanol, 16% w/
w solution of hydrogen chloride–methanol (4 eq.) was added
dropwise. The reaction was stirred for 1 hour at room tem-
perature and then the solvent was removed under vacuum.
The crude product was evaporated twice from EtOAc, then
recrystallized from dry ethanol to yield the pure product.
2e – 1-benzyl-3-cyano-1-{4-[4-(7-phenoxyheptyl)piperazin-1-
yl]but-1-yl}-guanidine trihydrochloride. C30H44N6O·3HCl
·1.5H2O. M = 641.13. White solid. 64.2% yield. mp: 124.4–126.4
°C. 1H NMR (600 MHz, D2O) δ ppm 7.47–7.44 (m, 2H
arom.),
7.42–7.39 (m, 1Harom.), 7.37–7.35 (2Hphenoxy., C(CHCH)2CH),
7.29–7.28 (m, 2Harom), 7.04–6.99 (m, 3Hphenoxy., C(CHCH)2CH),
4.75 (s, 2H, CH2Ph), 4.07–4.05 (t, 2H, OCH2, J = 6.49 Hz), 3.59–
3.51 (m, 10H: 8Hpip, CH2CH2NC(N)), 3.25–3.19 (m, 4H:
CH2N
piperazine), 1.76–1.71 (m, 8H, CH2CH2CH2), 1.45–1.38 (m,
6H, CH2CH2CH2).
13C NMR (600 MHz, D2O) δ ppm 158.19
(1Cquat./phenoxy., CO), 155.89 (1Cquat., CNH), 153.94 (1Cquat.,




(2Carom.), 126.88 (2Carom.), 121.53 (1Cphenoxy., C(CHCH)2CH),
115.07 (2Cphenoxy., C(CHCH)2CH), 68.65 (1C, PhOCH2), 57.07
(1C, CH2N
piperazine), 56.27 (1C, CH2N
piperazine), 52.15 (1C,
NCH2Ph), 48.68, 48.63 (5C: 4C
piperazine., CH2CH2NC(N)), 28.22
(1C, CH2CH2CH2), 27.81 (1C, CH2CH2CH2), 25.49 (1C,
CH2CH2CH2), 24.92 (1C, CH2CH2CH2), 23.39 (1C,
CH2CH2CH2), 23.26 (1C, CH2CH2CH2), 20.72 (1C,
CH2CH2CH2). Anal. calcd: C, 56.20; H, 7.86; N, 13.11. Found: C,
56.37; H, 8.11; N, 13.05.
Synthesis of 1,4-bisĲ7-phenoxyheptyl)piperazine dihydro-
chloride 2g. A 4 M solution of hydrogen chloride–dioxane (3
eq.) was added dropwise to a solution of 1,4-bisĲ7-
phenoxyheptyl)piperazine (2g.1) (1 eq.) in chloroform. The re-
action was stirred overnight at room temperature, then the
solvent was removed under vacuum. The crude product was
evaporated twice with chloroform and twice with EtOAc, then
recrystallized from dry methanol to yield the pure product.
2g – 1,4-bisĲ7-phenoxyheptyl)piperazine dihydrochloride.
C30H46N2O2·2HCl. M = 539.64. White solid. 82.6% yield. mp:
244.0–246.0 °C with decomposition. 1H NMR (600 MHz, CD3OD)
δ ppm 7.26–7.23 (m, 4Hphenoxy., C(CHCH)2CH), 6.91–6.88 (m,
6Hphenoxy., C(CHCH)2CH), 3.99–3.97 (t, 4H, OCH2, J = 6.33 Hz),
3.90–3.31 (br, 8Hpiperazine), 3.19 (m, 4H, CH2N
piperazine), 1.81–
1.77 (qt, 8H, CH2CH2CH2), 1.56–1.51 (qt, 4H, CH2CH2CH2),
1.49–1.46 (m, 8H, CH2CH2CH2).
13C NMR (600 MHz, CD3OD) δ
ppm 160.54 (2Cquat./phenoxy., CO), 130.41 (4Cphenoxy.,
C(CHCH)2CH), 121.57 (2C
phenoxy., C(CHCH)2CH), 115.53
(4Cphenoxy., C(CHCH)2CH), 68.74 (2C, OCH2), 57.62 (2C
piperazine),
57.48 (2C,CH2N
piperazine), 57.33 (2Cpiperazine), 30.25 (2C,
CH2CH2CH2), 29.84 (2C, CH2CH2CH2), 27.49 (2C, CH2CH2CH2),
26.93 (2C, CH2CH2CH2), 25.12 (2C, CH2CH2CH2). Anal. calcd: C,
66.77; H, 8.97; N, 5.19. Found: C, 66.38; H, 9.35; N, 5.16.
3.2. In vitro pharmacology
All experiments with animals (guinea pigs and rats) were
performed in compliance with the Polish legislation
concerning the protection and welfare of animals used for
scientific purposes and followed the university guidelines. All
animal procedures have been approved by the 9 Local Ethical
Committee for Animal Experiments in Lodz, approval no. 60/
ŁB681/2013 and 86/ŁB696/2013, respectively. The HEK293T
cell line was kindly provided by Prof. Dr Rob Leurs, Vrije
Universiteit Amsterdam; the HEK-hH3R cell line was kindly
provided by Prof. Dr. Jean-Charles Schwartz, Bioprojet,
France; CHO cells stably expressing hH4R were obtained from
PerkinElmer, Waltham, MA, U.S.
3.2.1. Histamine H3 receptor antagonistic activity of com-
pounds 2a–h. In the first step, all the newly synthesized com-
pounds were tested for histamine H3 receptor antagonistic ef-
fects in vitro, following standard methods, using an
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Male guinea pigs weighing 300–400 g were sacrificed and
a portion of the small intestine, 20–50 cm proximal to the
ileocaecal valve (jejunum), was removed and placed in Krebs
buffer (composition (mM) NaCl 118; KCl 5.6; MgSO4 1.18;
CaCl2 2.5; NaH2PO4 1.28; NaHCO3 25; glucose 5.5 and indo-
methacin (1 × 10−6 mol L−1)). Whole jejunum segments (2
cm) were prepared and mounted between two platinum
electrodes (4 mm apart) in 20 mL Krebs buffer, continuously
gassed with 95% O2 : 5% CO2 and maintained at 37 °C. Con-
tractions were recorded isotonically under 1.0 g tension with
a Hugo Sachs Hebel-Messvorsatz (Tl-2)/HF-modem (Hugo
Sachs Elektronik, Hugstetten, Germany) connected to a pen
recorder. The equilibration was performed for one hour with
washings every 10 minutes. The muscle segments were then
stimulated at a maximum between 15 and 20 volts, continu-
ously at a frequency of 0.1 Hz for a duration of 0.5 ms, with
rectangular-wave electrical pulses, delivered by a Grass Stimu-
lator S-88 (Grass Instruments Co., Quincy, USA). After 30 min
of stimulation and five minutes before adding (R)-α-
methylhistamine, pyrilamine (1 × 10−5 mol L−1 concentration
in an organ bath) was added, and then cumulative concentra-
tion–response curves (half-log increments) of (R)-α-
methylhistamine, a histamine H3 receptor agonist, were
recorded until no further change in response was found. Five
minutes before adding the tested compounds, pyrilamine (1
× 10−5 mol L−1 concentration in an organ bath) was added,
and after 20 minutes cumulative concentration–response
curves (half-log increments) of (R)-α-methylhistamine, an his-
tamine H3 receptor agonist, were recorded until no further
change in response was found. Statistical analysis was carried
out with Student's t-test. In all the tests, a p < 0.05 was con-
sidered statistically significant. The potency of an antagonist
is expressed by its pA2 value, calculated from the Schild
31 re-
gression analysis where at least three concentrations were
used. The pA2 values were compared with the potency of
thioperamide.
3.2.2. H1 antagonistic activity of compounds 2a–h. All the
final compounds were tested for H1 antagonistic effects
in vitro, following standard methods, using the guinea pig il-
eum.30 The donors were male guinea pigs (300–400 g) as men-
tioned above. The excised ileum was placed in phosphate
buffer at room temperature (pH 7.4) containing (mM) NaCl
(136.9), KCl (2.68), and NaHPO4 (7.19). The intraluminal con-
tent was flushed and segments of about 2 cm long were cut
and mounted for isotonic contractions in water mixed with 20
mL organ baths filled with oxygenated (O2 : CO2 = 95 : 5, v/v)
Krebs buffer containing (mM) NaCl (117.5), KCl (5.6), MgSO4
(1.18), CaCl2 (2.5), NaH2PO4 (1.28), NaHCO3 (25), glucose (5.5)
and indomethacin (1 10−6 mol L−1) at 37 °C under a constant
load of 0.5 g. After a 30 min equilibration period with wash-
ings every 10 min, a submaximal priming dose of histamine
(1 mM) was given and washed out (standard washing proce-
dure: 3 changes of buffer for 30 min). After washing out, the
antagonistic activity of the given compounds was measured
by recording a concentration–response curve (CRC) for hista-
mine in the presence of the tested compounds which were
added 10 min before histamine. This procedure was repeated
with higher concentrations of the compounds. The antago-
nism has a competitive nature causing a parallel shift in the
CRC. The pA2-values were calculated according to
Arunlakshana and Schild.31 The pA2 values were compared
with the affinity of pyrilamine.
3.2.3. Antagonist binding to the rat histamine H3 receptor
(rH3R), human histamine H3 receptor (hH3R), and human
histamine H4 receptor (hH4R)
3.2.3.1. Antagonist binding to the rat histamine H3 receptor
(rH3R). The affinities of the most active compounds 1a, 1c and
1d were evaluated by measuring the displacement curve of [3H]-
Nα-methylhistamine on the rat (rH3R) histamine H3 receptor in
HEK-293Tcell membranes as described by Bongers.32
Cell culture and transfection
Human embryonic kidney cells (HEK293T) were cultured in
DMEM supplemented with 10% fetal bovine serum and 100 IU
mL−1 penicillin and 100 μg mL−1 streptomycin at 37 °C and 5%
CO2. The day prior to transfection, two million cells were
seeded in 10 cm dishes. Approximately four million cells were
transfected by the polyethyleneimine (PEI) method with 5 μg of
cDNA at a ratio of 1 : 4 (DNA : PEI). Briefly, 0.5 μg of pcDNA3-
rH3R and 4.5 μg of empty plasmid (pcDNA3.1) were mixed with
20 μg of 25 kDa linear PEI in 500 μl of 150 mM NaCl and incu-
bated for 30 minutes at 22 °C. Meanwhile, the medium from
10 cm dishes was replaced with fresh culture medium and the
transfection mix was subsequently added dropwise to the cells
and incubated for 48 hours at 37 °C and 5% CO2.
Crude membrane extracts
Forty-eight hours after transfection, cells were washed with
ice-cold phosphate-buffered saline (PBS) and scrapped and
the homogenate was centrifuged for 10 minutes at ∼2000g, 4
°C. The supernatant was aspirated and cell pellets were
resuspended in 1 ml of ice-cold PBS and centrifuged again
under the same conditions; the supernatant was aspirated
and the membranes were stored at −20 °C until further use.
[3H]-Nα-methylhistamine binding
Frozen cell pellets were dissolved in 50 mM Tris-HCl buffer
(pH 7.4), homogenized by sonication (40 Watt Labsonic 1510)
for 3 to 5 s and kept on ice until use. Cell homogenates were
incubated in the presence of increasing concentrations of
[3H]-NαMH (0–20 nM) in 50 mM Tris-HCl binding buffer for
saturation binding. Total and non-specific binding was deter-
mined in the absence or presence of excess non-labeled thio-
peramide (10 μM), respectively. For the competitive binding
assay, the homogenates were incubated with increasing con-
centrations of receptor ligands (10−11 to 10−4 M) and ∼2.5 nM
[3H]-NαMH. All assays were incubated at 25 °C for two hours
on a shaking table (600 rpm). The reaction was terminated by
rapid filtration into 0.5% polyethyleneimine pre-soaked glass
fiber C plates (GF/C Perkin Elmer) followed by three washes
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dried for one hour at 50 °C and scintillation liquid was added
to each well (25 μl). The retained radioactivity was deter-
mined by liquid scintillation counting in a Wallac Microbeta
(Perking Elmer). Protein determination for Bmax estimation
was performed with a Pierce BCA protein assay kit and mea-
sured by spectrophotometry in a Power Wave X340 (Biot-Tek
Instruments Inc.).
Chemicals
Dubelcco's modified Eagle's medium (DMEM), phosphate
buffered saline (PBS) trizma base, and polyethyleneimine so-
lution (50%, PEI) were purchased from Sigma Aldrich. Fetal
bovine serum (FBS, Bodinco BV, the Netherlands), penicillin/
streptomycin (streptomycin 10 000 IU mL−1; penicillin and
10 000 μg mL−1, Thermo Fischer Scientific), linear 25 kDa
polyethyleneimine (PEI, Polysciences, Warrington, PA, U.S.),
[3H]-N-α-methylhistamine (specific activity 79.7 Ci mmol−1,
Perkin Elmer), thioperamide, (Abcam), and histamine (TCI).
3.2.3.2. Antagonist binding to the human histamine H3
receptor (hH3R). Competitive radioligand binding to cell
membranes of HEK293 cells stably expressing the human
histamine H3 receptor was conducted as presented in detail
elsewhere.34 [3H]-Nα-methylhistamine (1 nM) was incubated
with the cell membrane preparation in 50 mM Tris/HCl, 5
mM MgCl2 assay buffer (35 μg of protein in a single assay
tube) and serial dilutions of the tested compounds for 1 h at
25 °C with continuous shaking (400 rpm). Total radioligand
binding was measured in the presence of 2.5% DMSO and
nonspecific binding was assessed by addition of unlabeled
(R)Ĳ−)-α-methylhistamine (20 μM). The bound radioligand was
detected after filtration of the incubation mixture through
GF/B filters presoaked with 0.5% (m/v) polyethyleneimine.
For the calculation of Ki values, the Cheng–Prusoff equation
and experimentally determined radioligand KD value of 0.34
were used.
3.2.3.3. Antagonist binding to human hH4R. Histamine H4
receptor affinity was evaluated on membrane preparations
from CHO cells, expressing the recombinant human
histamine H4 receptor. Experiments were performed as
described before.35 In brief: cell membranes (15 μg protein
per sample) were incubated for 1 h at 25 °C with tritiated
histamine (10 nM) and serial dilutions of the evaluated
compounds in assay buffer (50 mM Tris/HCl and 5 mM
EDTA in ultrapure water, pH 7.4). Non-specific binding was
determined in the presence of 100 μM un-labeled histamine.
The bound radioligand was collected on GF/B filters
pretreated with 0.3% (m/v) polyethyleneimine and the cap-
tured radioactivity was measured by liquid scintillation
counting. Affinity values (pKi) were calculated according to
the Cheng–Prusoff equation (KD for [
3H]histamine: 9.7 nM).
3.3. Verification of in vivo activity for compounds 1a, 1c, and 1d
The histamine H3 receptor antagonistic activity of 1a, 1c, and
1d toward the brain histamine receptors was assessed in vivo
by the intravital study of the feeding behavior and then by
post-mortem analyses of neurotransmitter systems in the
brain tissues from the treated rats.
For the first stage, food intakes were measured daily dur-
ing subchronic drug administration. The histamine H3 recep-
tor antagonists show the ability to inhibit appetite.
Male rats aged between 9 and 10 weeks old were used. In ex-
periments with compound 1a, Wistar rats were used; the Lewis
strain was employed with compounds 1c and 1d due to a short-
age of Wistar rats of the required age. Although these rat
strains differ somewhat in the cerebral amine concentrations
and enzyme activities, both responded in the same way to
ciproxifan as checked. Metabolic cages (Tecniplast, Italy) were
used to measure feed consumption. The cages have a standard-
ized size that allows the animal to move inside freely. Through-
out the adaptive period and the experimental one, access to
feed and fluid was unlimited. The illumination cycle was stable
at 12 h light on, 12 h light off. The rats were individually placed
in the cages four days before the onset of treatment to adapt to
a new environment and conditions of housing. The consump-
tion and excretion were recorded every morning and the moni-
toring continued as long as the rats stayed in metabolic cages.
The treatment ran for five days from the fifth day.
Subcutaneous injections of either 1a, 1c, 1d or ciproxifan,
which was used as a reference (3 mg kg−1 per day to n = 8 rats),
in the study group and physiological saline (0.2 ml per day to n =
8 rats) in the case of the control group were conducted. Records
of consumption were taken as g of feed per 100 g body mass.
3.3.1. Post-mortem biochemical analyses. Post-mortem
brain analyses included estimation of the amine neurotrans-
mitter concentrations as well as the activities of the degrada-
tive enzymes HNMT, MAO-A and MAO-B.
The rats were sacrificed 24 hours after the last injection.
The brains were collected, cerebral cortex separated
according to the Glowinski and Iversen method,38 immedi-
ately frozen in liquid nitrogen and kept at −80 °C until
assayed. The thawed tissue was homogenized in 3 volumes of
bi-distilled water and aliquots were further processed to esti-
mate the concentrations of the amines and activities of the
enzymes. The amine concentrations: dopamine, noradrena-
line, and serotonin were measured by RIA and histamine by
Research ELISA kits (DIAsource ImmunoAssays S.A. Louvain-
la-Neuve, Belgium). The enzyme activities of histamine
N-methyltransferase and monoamine oxidase A and B were
estimated by radioisotopic assays according to Taylor and
Snyder41 and Fowler and Tipton42 with modifications by
Gómez et al.,43 respectively. For MAO-A, serotonin (5-[2-14C]-
hydroxytryptamine binoxalate) was used as a substrate and
for MAO-B, β-[ethyl-1-14C]-phenylethylamine hydrochloride
was used as a substrate; clorgyline (MAO-A) and deprenyl
(MAO-B) (fin. conc. 10−9 M) were used as enzyme inhibitors.
The protein was measured by the Lowry method.44
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